TY - JOUR T1 - Evidence for treatment with estradiol for women with SARS-CoV-2 infection JF - medRxiv DO - 10.1101/2020.08.21.20179671 SP - 2020.08.21.20179671 AU - Ute Seeland AU - Flaminia Coluzzi AU - Maurizio Simmaco AU - Cameron Mura AU - Philip E. Bourne AU - Max Heiland AU - Robert Preissner AU - Saskia Preissner Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179671.abstract N2 - Background Given that an individual’s age and gender are strongly predictive of COVID-19 outcomes, do such factors imply anything about preferable therapeutic options?Methods An analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in five-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic hormone administration in women. The primary outcome for estradiol therapy was death. Odds Ratios (ORs) and Kaplan-Meier survival curves were analyzed for 37,086 COVID-19 women in two age groups: pre- (15-49 years) and post-menopausal (>50 years).Results The incidence of SARS-CoV-2 infection is higher in women than men (about +15%) and, in contrast, the fatality rate is higher in men (about +50%). Interestingly, the relationships between these quantities are also linked to age. Pre-adolescent girls had the same risk of infection and fatality rate as boys. Adult premenopausal women had a significantly higher risk of infection than men in the same five-year age stratum (about 16,000 vs. 12,000 cases). This ratio changed again in postmenopausal women, with infection susceptibility converging with men. While fatality rates increased continuously with age for both sexes, at 50 years there was a steeper increase for men. Thus far, these types of intricacies have been largely neglected. Because the hormone 17ß-estradiol has a positive effect on expression of the human ACE2 protein—which plays an essential role for SARS-CoV-2 cellular entry—propensity score matching was performed for the women’s sub-cohort, comparing users versus non-users of estradiol. This retrospective study of hormone therapy in female COVID-19 patients shows that the fatality risk for women >50 yrs receiving estradiol therapy (user group) is reduced by more than 50%; the OR was 0.33, 95 % CI [0.18, 0.62] and the Hazard Ratio was 0.29, 95% CI[0.11,0.76]. For younger, pre-menopausal women (15-49 yrs), the risk of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher endogenous estradiol levels.Conclusions As of this writing, still no effective drug treatment is available for COVID-19; since estradiol shows such a strong improvement regarding fatality in COVID-19, we suggest prospective studies on the potentially more broadly protective roles of this naturally occurring hormone.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPortions of this work were supported by the University of Virginia School of Data Science and by NSF CAREER award MCB-1350957.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable, as only anonymized data for an international cohort were utilized. (..."a large international COVID-19 cohort comprising 68,466 cases. Sub-cohorts were disaggregated by age (15+ years) and sex before statistical analyses were performed...)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe utilized the TriNetX platform. TriNetX provides details on the data provenance and/or offers the necessary access to audit the processes. TriNetX also makes the data available for a third-party audit.COVID-19Coronavirus Disease 2019ACEAngiotensin-converting enzymeOR / HR / CIOdds Ratio / Hazard Ratio / Confidence IntervalSARS-CoV-2Severe Acute Respiratory Syndrome-Coronavirus-2AT2RAngiotensin II receptor Type 2RAASRenin angiotensin aldosterone systemIL-6Interleukin-6Ang1–7Angiotensin 1–7EHRElectronic Health RecordsRWEReal-world evidence ER -